Preferential Cochleotoxicity of Cisplatin

Frontiers in Neuroscience

Pattarawadee Prayuenyong²  David M. Baguley⁴  Corné J. Kros⁵  Peter S. Steyger⁶ 

[1] Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand;Hearing Sciences, Division of Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom;National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham, United Kingdom;Nottingham Audiology Services, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom;School of Life Sciences, University of Sussex, Brighton, United Kingdom;Translational Hearing Center, Biomedical Sciences, Creighton University, Omaha, NE, United States;

关键词: cisplatin;    ototoxicity;    cochlea;    vestibular;    cochleotoxicity;    vestibulotoxicity;   

DOI  :  10.3389/fnins.2021.695268

来源: DOAJ

【 摘 要 】

Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to cisplatin. The existing literature suggests, however, that cisplatin might have different patterns of drug trafficking across the blood-labyrinth-barrier, or different degrees of cisplatin uptake to the hair cells in the cochlear and vestibular compartments. This review proposes an explanation for the preferential cochleotoxicity of cisplatin based on current evidence as well as the anatomy and physiology of the inner ear. The endocochlear potential, generated by the stria vascularis, acting as the driving force for hair cell mechanoelectrical transduction might also augment cisplatin entry into cochlear hair cells. Better understanding of the stria vascularis might shed new light on cochleotoxic mechanisms and inform the development of otoprotective interventions to moderate cisplatin associated ototoxicity.

【 授权许可】

Unknown